Viamet Pharmaceuticals Corp (VMET) Peer Comparison
$10.41
$-0.32
(-2.98%)
As on 26-Aug-2026 16:26EDT
Market cap
$1,155 Mln
Revenue (TTM)
$73 Mln
P/E Ratio
29.5
P/B Ratio
2.9
Div. Yield
0 %
Edit
| Viamet Pharmaceuticals Corp (VMET) | Lineage, Inc. (LINE) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
1,155 | 10,434 | 878 | 923 | 7 |
Revenue ($ Mln) |
73 | 5,371 | 1,653 | 208 | -- |
Net Profit ($ Mln) |
36.72 | -169.00 | 48.98 | 52.16 | -10.47 |
Net Margin (%) |
50.13 | -3.15 | 2.96 | 25.13 | -- |
RoE (%) |
11.69 | -1.85 | 3.61 | 30.61 | -130.80 |
Price to Earnings |
29.47 | -- | 12.25 | 17.86 | -- |
Price-To-Book |
2.89 | 1.20 | 0.63 | 4.83 | 1.73 |
Income Statement ($ Mln)
| Viamet Pharmaceuticals Corp (VMET) | Lineage, Inc. (LINE) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
34.76 | 5,355.00 | 1,676.50 | 148.47 | 0.00 |
|
Cost of Revenue
|
21.28 | 4,529.00 | 1,210.50 | 73.46 | -- |
|
Gross Profit
|
13.48 | 826.00 | 466.00 | 75.02 | -- |
|
Operating Expenses
|
7.64 | 574.00 | 250.60 | 20.76 | 4.24 |
|
Operating Profit (EBIT)
|
5.84 | 252.00 | 215.40 | 54.26 | -4.24 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
29.60 | -115.00 | 113.40 | 54.70 | -4.23 |
|
Provision for Tax
|
9.27 | -2.00 | 37.20 | 20.96 | -- |
|
Profit after Tax (Net Income)
|
20.33 | -98.00 | 76.20 | 33.74 | -4.23 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Viamet Pharmaceuticals Corp (VMET) | Lineage, Inc. (LINE) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
233.96 | 8,246.00 | 1,328.50 | 150.73 | 11.22 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
151.17 | 8,394.00 | 1,373.80 | 28.86 | 0.22 |
|
Current Liabilities
|
32.88 | 1,548.00 | 574.30 | 28.85 | 0.14 |
|
Total Liabilities
|
418.01 | 19,185.00 | 3,276.60 | 208.45 | 11.58 |
Assets ($ Mln)
| Viamet Pharmaceuticals Corp (VMET) | Lineage, Inc. (LINE) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
393.79 | 17,946.00 | 2,735.90 | 96.72 | 0.35 |
|
Current Assets
|
24.22 | 1,239.00 | 540.70 | 111.72 | 11.23 |
|
Total Assets
|
418.01 | 19,185.00 | 3,276.60 | 208.45 | 11.58 |
|
Total Debt*
|
141.00 | 8,657.00 | 1,225.30 | 0.07 | 0.35 |
|
Net Current Assets
|
-8.66 | -309.00 | -33.60 | 82.87 | 11.09 |
Cashflow ($ Mln)
| Viamet Pharmaceuticals Corp (VMET) | Lineage, Inc. (LINE) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
16.95 | 943.00 | 322.00 | 52.98 | -10.48 |
|
Cash Flow from Investing Activities
|
-159.46 | -1,067.00 | -350.90 | -20.34 | -- |
|
Cash from Financing Activities
|
144.84 | 14.00 | 54.70 | 30.07 | 15.31 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Viamet Pharmaceuticals Corp (VMET) | Lineage, Inc. (LINE) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
6.94 | -0.60 | 3.17 | 29.00 | -70.02 |
|
ROE (%)
|
9.13 | -1.16 | 6.23 | 29.64 | -72.09 |
|
ROA (%)
|
6.27 | -0.52 | 2.52 | 21.39 | -69.85 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
58.49 | -1.83 | 4.55 | 22.72 | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Viamet Pharmaceuticals Corp (VMET) | Lineage, Inc. (LINE) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
1.89 | 0.00 | 0.14 | 0.61 | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
930.56 | 85.24 | 17.96 | 76.17 | -1,068.75 |
|
EPS Growth (%)
|
22.18 | 0.85 | -0.92 | 0.56 | -253.40 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Viamet Pharmaceuticals Corp (VMET) | Lineage, Inc. (LINE) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -81.43 | 10.27 | 15.37 | -0.10 |
|
Price / Book Value
|
-- | 0.97 | 0.59 | 3.44 | 0.04 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-- | 15.81 | 5.70 | 6.90 | 1.00 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Viamet Pharmaceuticals Corp (VMET) | Lineage, Inc. (LINE) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.60 | 1.05 | 0.92 | 0.00 | 0.03 |
|
Short term debt to equity ratio
|
-- | 0.02 | 0.16 | 0.00 | 0.01 |
|
Current Ratio
|
0.74 | 0.80 | 0.94 | 3.87 | 81.93 |
|
Quick Ratio
|
-- | 0.71 | 0.79 | 2.86 | -- |
|
Interest Coverage
|
3.43 | 0.57 | 2.87 | 55.05 | -493.92 |
Operating Efficiency Ratios
| Viamet Pharmaceuticals Corp (VMET) | Lineage, Inc. (LINE) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
27.70 | 16.73 | 6.33 | 1.38 | -- |
|
Asset Turnover
|
0.11 | 0.28 | 0.55 | 0.94 | 0.00 |
|
Receivable days
|
52.53 | 58.73 | 17.21 | 2.99 | -- |
|
Inventory Days
|
-- | 13.39 | 22.86 | 100.11 | -- |
|
Payable days
|
35.28 | 93.39 | 27.62 | 59.08 | -- |
|
Cash Conversion Cycle
|
-- | -21.28 | 12.44 | 44.01 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
